" class="no-js "lang="en-US"> Cumulus Neuroscience - Medtech Alert
Friday, August 29, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Cumulus Neuroscience | Pharmtech Focus

Cumulus Neuroscience

About Cumulus Neuroscience

Cumulus Neuroscience

We’re developing faster, more effective tools to help our partners solve the biggest healthcare challenges in neurodegeneration and psychiatry.

Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform. In clinical trials it provides the critical data and insights needed to accelerate the delivery of more effective CNS drugs to patients. This addresses the significant unmet need for faster, more robust and cost-effective execution and evaluation of clinical trials in neuroscience.

Related Story

Clinical Trials

 Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial | MTA

Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer's Dementia Validation Trial

May 31 2023

Cumulus Neuroscience, a global digital health company focused on advancing neuroscience clinical trials and patient […]

News

 Cumulus Neuroscience Expands Development Support of Novel Precision CNS Therapeutics | MTA

Cumulus Neuroscience Expands Development Support of Novel Precision CNS Therapeutics

April 11 2023

Cumulus Neuroscience, a global digital health company focused on advancing neuroscience clinical trials and patient […]

Appointments

 Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti

Cumulus Neuroscience Appoints Digital Health and Pharmaceutical Executive Aman Bhatti, MD as Chief Executive Officer

September 22 2022

Cumulus Neuroscience (Cumulus; the Company), a global digital health company developing multi-domain digital biomarkers for the […]

Clinical Trials

 Cumulus Neuroscience Announces £6 million Funding Round Led by the Dementia Discovery Fund and joined by LifeArc and UK Future Fund | Pharmtech Focus

Cumulus Neuroscience Announces £6 million Funding Round

May 5 2021

Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a £6m financing round led […]